Our present observation could be of potential clinical relevance given the existence of several AURKA inhibitors that are currently being tested in patients with breast cancer (NCT02187991, phase 2 with alisertib, and NCT02134067, phase 1 with TAS-119). Here, AURKA is linked to breast cancer.